Rigel Pharmaceuticals | RIGL - Stammkapital

Aktienkurs
26.27
Täglich Wechseln
-1.82 -6.48%
Monatlich
-3.98%
Jährlich
43.87%
Q2 Prognose
28.79




Stammkapital Veränderung Datum
Agenus USD 35.32M 2.51M 2025-12
Amgen USD 540M 1000K 2026-03
Anika Therapeutics USD 13.89M 532K 2025-12
Arrowhead Research USD 135.7M 2.44M 2025-09
AstraZeneca USD 1.55B 73K 2026-03
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Celldex Therapeutics USD 66.55M 102K 2025-12
Daiichi Sankyo JPY 1.85B 9K 2025-12
Eli Lilly USD 943.5M 3.33M 2026-03
Halozyme Therapeutics USD 117.78M 259K 2025-12
Heron Therapeutics USD 188.31M 4.99M 2025-12
Intrexon USD 0 0 2024-06
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
Karyopharm Therapeutics USD 18.31M 18.3M 2025-12
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
MacroGenics USD 63.32M 60K 2025-12
Neurocrine Biosciences USD 100.6M 500K 2026-03
Pfizer USD 5.7B 13M 2026-03
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Rigel Pharmaceuticals USD 17K 158K 2024-06
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Veracyte USD 79.79M 743K 2026-03